Duloxetine
Raising the availability of two neurotransmitters at once, duloxetine inhibits the reuptake of both serotonin and norepinephrine, placing it in the serotonin-norepinephrine reuptake inhibitor class. The dual action supports mood while also engaging pain-modulating pathways in the nervous system, which is why the drug treats not only depression and anxiety but also chronic nerve pain and fibromyalgia. A small molecule (C18H19NOS) with a half-life of about 12 hours, it is generally dosed once or twice daily. Its effect on descending pain pathways distinguishes it from antidepressants that act on serotonin alone and underlies its use in painful physical conditions. Duloxetine is an approved medicine bridging psychiatric and pain-related indications.
A serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression, anxiety, nerve pain, and fibromyalgia. It works by increasing the availability of serotonin and norepinephrine in the brain.
分子量
297.4150 g/mol
LogP
4.30
TPSA
49.50 Ų
リピンスキーの五則
適合
治療領域
薬物分類
作用機序
Serotonin-norepinephrine reuptake inhibitor (SNRI).
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Serotonin-norepinephrine reuptake inhibitor (SNRI).
2D構造
Cite this structure
Embed this structure
SMILES
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
InChI
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
Molecular Formula
C18H19NOS
HBD / HBA
1 / 3
回転可能結合数
6
重原子数
21
Duloxetine, a serotonin-norepinephrine reuptake inhibitor, combined with tramadol markedly elevates the risk of serotonin syndrome.
Fluoxetine is a potent CYP2D6 inhibitor that substantially increases duloxetine plasma levels, while both agents also increase serotonin syndrome risk.
Combining duloxetine and sertraline, two serotonergic antidepressants, markedly increases the risk of serotonin syndrome without added efficacy.
Duloxetine and pregabalin are commonly co-prescribed for neuropathic pain with complementary mechanisms; additive CNS effects including dizziness, somnolence, and cognitive impairment can occur.
Duloxetine and sumatriptan co-administration carries a serotonin syndrome risk due to complementary mechanisms of serotonergic stimulation.
Carbamazepine substantially reduces duloxetine plasma levels through CYP1A2 and CYP3A4 induction, risking loss of antidepressant efficacy.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression, anxiety, nerve pain, and fibromyalgia. It works by increasing the availability of serotonin and norepinephrine in the brain.
Serotonin-norepinephrine reuptake inhibitor (SNRI).
Key pharmacokinetic parameters for Duloxetine: Half-life: 12 hours.
Yes, Duloxetine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1175. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60835. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="duloxetine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/duloxetine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/duloxetine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/duloxetine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="duloxetine"></drugfyi-drug>